This is a third-party event.
Jon Burrows, CEO, will present the HY results which are released on the 15th June and update on current performance.
Company Description: Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Speaker: Jon Burrows, CEO
Jon’s 25 year career in science and medicine has been built on increasing levels of responsibility in scientific leadership, business development, commercialization and executive management at both early-stage biotech and large multinational biomedical entities including Pharmacia/SUGEN, Rigel, Chiron, Novartis, Ventana, Roche, Expression Pathology and OncoPlex Diagnostics.
In his early career, Jon was in oncology drug development, where he became skilled at driving molecular diagnostics tied to drug development to advance precision medicine and advocate for personalized healthcare.
Most recently Jon was a Managing Partner at Oncology Partners (NYC), a consulting and clinical advisory firm he co-founded, focused on providing strategic counsel to development stage pharma, biotech, medical devices and diagnostic companies.
Previously Jon was president and CEO of OncoPlex Diagnostics.
Register in advance for this webinar: https://us02web.zoom.us/webinar/register/5316229995714/WN_8keLBlkxQpiVKAf1uBV_3w